nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.02.2009 | Short Communication

Detection of complete response to imatinib mesylate (Glivec^®/Gleevec^®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

verfasst von: Mehmet Emin Kalender, Alper Sevinc, Mustafa Yilmaz, Coskun Ozsarac, Celalettin Camci

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Malignant mesenchymal tumors consist of approximately 10% of uterine tumors. The majority of uterine sarcomas are leiomyosarcoma and endometrial stromal sarcoma (ESS). Surgery, radiotherapy, chemotherapy, and hormonal therapy are used for the treatment of ESS. Imatinib mesylate is indicated in the management of gastrointestinal stromal tumor and chronic myelogeneus leukemia. There is an interest to use imatinib mesylate in the treatment of c-kit positive ESS. We reported a case of 42-year-old female low-grade ESS progressed on chemotherapy and presented with objective response to imatinib mesylate. The treatment response was evaluated with FDG PET/CT. Complete metabolic response was detected. FDG PET, a sensitive method for tumor response evaluation on the basis of tumor metabolism changes, is useful for the evaluation of imatinib treatment in low-grade ESS.

Moinfar F, Azodi M, Tavassoli FA (2007) Uterine sarcomas. Pathology 39:55–71PubMedCrossRef

Hasiakos D, Papakonstantinou K, Kondi-Paphiti A, Fotiou S (2007) Low-grade endometrial stromal sarcoma of the endocervix. Report of a case and review of the literature. Eur J Gynaecol Oncol 28:483–486PubMed

De Vita Jr VT, Hellman S, Rosenberg SA (2005) Cancer: principles and practice of oncology. In: Burke Tw, Mundt AJ, Muggia FM (eds) Cancers of the uterine body. 7th edn. Chap. 32.2. Philadelphia, USA, pp 1341–1360

Sevinc A, Adli M, Kalender ME, Camci C (2007) Benign causes of increased serum CA-125 concentration. Lancet Oncol 8:1054–1055PubMedCrossRef

Sevinc A, Camci C, Turk HM, Buyukberber S (2003) How to interpret serum CA-125 levels in patients with serosal involvement? A clinical dilemma. Oncology 65:1–6PubMedCrossRef

Amant F, Moerman P, Cadron I, Neven P, Berteloot P, Vergote I (2003) The diagnostic problem of endometrial stromal sarcoma: report on six cases. Gynecol Oncol 90:37–43PubMedCrossRef

Lo KW, Yu MY, Cheung TH (2008) Low-grade endometrial stromal sarcoma with florid ıntravenous component. Gynecol Obstet Invest 66:8–11PubMedCrossRef

Veroux P, Veroux M, Nicosia A, Bonanno MG, Tumminelli MG, Milone P, Petrillo G (2000) Thrombectomy of the inferior vena cava from recurrent low-grade endometrial stromal sarcoma: case report and review of the literature. J Surg Oncol 74:45–48PubMedCrossRef

Ali RA, El-Hady el-SA, El-Zayat M (2008) Multilocular intrauterine cystic mass, atypical presentation of endometrial stromal sarcoma: a case report. Arch Gynecol Obstet 277:185–187PubMedCrossRef

10.

Wang KC, Liang DC, Su TH, Hung FY, Yang YC (1998) High-grade endometrial stromal sarcoma in a 10-year-old girl: case report. Changgeng Yi Xue Za Zhi 21:312–317PubMed

11.

Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS (2007) Low grade endometrial stromal sarcoma: a single center’s experience with 22 cases. Int J Gynecol Cancer (in press)

12.

Ashraf-Ganjoei T, Behtash N, Shariat M, Mosavi A (2006) Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol 4:50PubMedCrossRef

13.

Reich O, Regauer S (2007) Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 19:347–352PubMedCrossRef

14.

Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balaña C (2006) A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol 101:545–547PubMedCrossRef

15.

Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M, Stroobants S, Mortelmans L, Schoffski P, Van Oosterom A (2006) Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 26:1247–1252PubMed

16.

Van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423PubMedCrossRef

17.

Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A (2005) Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 25:4591–4594PubMed

18.

Sevinc A, Camci C, Yilmaz M, Buyukhatipoglu H (2007) The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective. Onkologie 30:645–648PubMedCrossRef

19.

Zincirkeser S, Sevinc A, Kalender ME, Camci C (2007) Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging. World J Gastroenterol 13:2261–2262PubMed

Titel: Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma
verfasst von: Mehmet Emin Kalender
Alper Sevinc
Mustafa Yilmaz
Coskun Ozsarac
Celalettin Camci
Publikationsdatum: 01.02.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0786-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Detection of complete response to imatinib mesylate (Glivec^®/Gleevec^®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies

Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand

A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients

Effect of antacid on imatinib absorption

Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie